- Home
- OBIO vs XFOR Comparison
OBIO vs XFOR Comparison
Compare OBIO & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- XFOR
- Stock Information
- Founded
- OBIO 2017
- XFOR 2014
- Country
- OBIO United States
- XFOR United States
- Employees
- OBIO N/A
- XFOR N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OBIO Health Care
- XFOR Health Care
- Exchange
- OBIO Nasdaq
- XFOR Nasdaq
- Market Cap
- OBIO 118.8M
- XFOR 118.4M
- IPO Year
- OBIO N/A
- XFOR N/A
- Fundamental
- Price
- OBIO $3.29
- XFOR $1.82
- Analyst Decision
- OBIO Strong Buy
- XFOR Strong Buy
- Analyst Count
- OBIO 5
- XFOR 3
- Target Price
- OBIO $14.20
- XFOR $72.33
- AVG Volume (30 Days)
- OBIO 303.1K
- XFOR 1.6M
- Earning Date
- OBIO 08-11-2025
- XFOR 08-07-2025
- Dividend Yield
- OBIO N/A
- XFOR N/A
- EPS Growth
- OBIO N/A
- XFOR N/A
- EPS
- OBIO N/A
- XFOR 2.16
- Revenue
- OBIO $2,886,000.00
- XFOR $31,364,000.00
- Revenue This Year
- OBIO $20.47
- XFOR $1,300.08
- Revenue Next Year
- OBIO $11.45
- XFOR N/A
- P/E Ratio
- OBIO N/A
- XFOR $0.84
- Revenue Growth
- OBIO 30.23
- XFOR N/A
- 52 Week Low
- OBIO $2.37
- XFOR $1.38
- 52 Week High
- OBIO $8.30
- XFOR $26.96
- Technical
- Relative Strength Index (RSI)
- OBIO 60.31
- XFOR 44.64
- Support Level
- OBIO $3.05
- XFOR $1.38
- Resistance Level
- OBIO $3.24
- XFOR $2.25
- Average True Range (ATR)
- OBIO 0.16
- XFOR 0.18
- MACD
- OBIO 0.03
- XFOR 0.10
- Stochastic Oscillator
- OBIO 93.75
- XFOR 50.57
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.